SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
Sorrento Therapeutics, Inc. (SRNE)
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm
Check Earnings Report
US:NASDAQ Investor Relations:
sorrentotherapeutics.com/investors
Company Research
Source: GlobeNewswire
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren, New Jersey, based clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. On April 2, 2020, Celularity announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for the use of its proprietary CYNK-001 in adults with COVID-19. Celularity also announced that it will immediately commence a Phase I/II clinical study including up to 86 patients with COVID-19. The collaboration between Sorrento and Celularity reflects the longstanding relationship between the two companies dating to Celularity’s inception. Celularity is preparing to launch CYNK-001 manufacturing at its new purpose-built cGMP/cGTP manufacturing facility in Florham Park, New Jersey. Sorrento
Show less
Read more
Impact Snapshot
Event Time:
SRNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRNE alerts
High impacting Sorrento Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRNE
News
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat